MIRM Mirum Pharmaceuticals, Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001759425
AI RATING
SELL
70% Confidence

Investment Thesis

Mirum demonstrates strong revenue growth of 54.7% YoY and improving loss metrics, supported by a solid balance sheet with $324.9M cash and zero debt. However, the company faces severe operational challenges with -$789.5M operating losses, -493.8% operating margin, and unsustainable free cash burn of $229.4M annually, providing only ~1.4 years of runway at current burn rates.

Strengths

  • + Strong revenue growth of 54.7% year-over-year indicates market demand and sales momentum
  • + Solid balance sheet with $324.9M in cash, $242.5M stockholders equity, and zero long-term debt provides financial flexibility
  • + Improving loss trajectory with diluted EPS improving 74.6% YoY suggests operational metrics are moving in the right direction

Risks

  • ! Massive operating losses of $789.5M with -493.8% operating margin indicate the business model is deeply unprofitable at scale
  • ! Free cash flow burn of $229.4M annually is unsustainable; at current rate provides approximately 1.4 years of cash runway
  • ! No clear timeline to profitability visible; company must dramatically reduce losses or accelerate revenue growth exponentially to sustain operations

Key Metrics to Watch

Financial Metrics

Revenue
159.9M
Net Income
-790.2M
EPS (Diluted)
$-13.43
Free Cash Flow
-229.4M
Total Assets
890.9M
Cash
324.9M

Profitability Ratios

Gross Margin N/A
Operating Margin -493.8%
Net Margin -494.2%
ROE -325.8%
ROA -88.7%
FCF Margin -143.5%

Balance Sheet & Liquidity

Current Ratio
2.09x
Quick Ratio
1.99x
Debt/Equity
0.00x
Debt/Assets
72.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T11:20:12.951096 | Data as of: 2026-03-31 | Powered by Claude AI